Kaspersky, the popular computer security firm based in Russia, has withdrawn its antitrust complaint against software giant Microsoft though the dispute is not totally gone. The security vendor lambasted Microsoft for allegedly taking advantage of its market influence to edge out antivirus providers.
The dispute arose from the new changes Microsoft introduced in the Creators Update that made Windows Defender the preferred security tool for Windows 10. The Creators Update removes some third-party security products from PCs that upgrade to the update. For Kaspersky, that means exposing users to security risks. The move also aims to force out security vendors, according to Eugene Kaspersky, founder and chief executive:
“Several years ago Microsoft decided to overhaul the Windows platform. Ostensibly this was in the name of better ease of usage, security, performance and so on. Behind the scenes what Microsoft was up to was elegantly seizing niche markets: squeezing independent developers out of them, taking their place, and offering users their own products, which in many cases were in no way better.” Said in the Kaspersky’s blog.
Full Content: Hot Hardware
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas